Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer

NCT06756932 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06756932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06756932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Recruiting
Start date
February 4, 2025
Completion date
July 30, 2027
Enrollment
120 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, hormone-receptor-positive breast cancer, metastatic breast cancer